Latest articles and price-sensitive announcements with AI sentiment classification.
Post-trial access is intended to support continued access to DMX-200 for patients with rare kidney disease focal segmental glomerular sclerosis. ... Read More The post Dimerix to provide kidney disease candidate access through post-trial pathways appeared first on Stockhead.
other announcement
Why Dimerix (ASX:DXB) Shares Are Back on the Radar Kalkine
Dimerix (ASX:DXB): Biotech Stock Pullback Puts Clinical Trial Watchers on Alert Kalkine
Dimerix (ASX: DXB) Explodes Higher as Biotech Traders Chase Momentum Kalkine
In a deal worth up to circa $480 million, Dimerix has signed an exclusive Asian licensing agreement for its rare ... Read More The post Dimerix inks Asian licensing deal worth up to $480 million for kidney disease drug appeared first on Stockhead.
Dimerix (ASX:DXB) Shares Rally After Unlocking New Commercial Opportunity for DMX-200 Kalkine
other announcement
other announcement
Highlights Phase 3 pathway gains stronger clarity Trial design aligned with regulators Program momentum remains steady Dimerix continues to refine its late-stage kidney disease program, strengthening clinical confidence and aligning with regulatory expectations while progressing toward a decisive trial outcome. The biotech landscape often shifts on subtle developments rather than headline-grabbing breakthroughs. One such example is Dimerix Ltd (ASX:DXB), which has recently taken a measu...
Shares In Dimerix (ASX:DXB) Fell 35% Today; Not About The Data, But About the Timing Stocks Down Under
other announcement
Dimerix to conduct blinded review of ACTION3 data later this month to confirm statistical assumptions for primary endpoint ... Read More The post Dimerix to conduct blinded review of phase III kidney disease trial data appeared first on Stockhead.
other announcement
other announcement
Dimerix’s ACTION3 study DMX-200 in focal segmental glomerulosclerosis doses final adult patient with 333 patients recruited ... Read More The post Dimerix doses final patient in Phase III kidney disease trial as enrolment exceeds target appeared first on Stockhead.
other announcement
other announcement
other announcement
other announcement
other announcement
other announcement
other announcement
other announcement
director_dealing announcement
other announcement
other announcement
other announcement
other announcement
other announcement
other announcement
director_dealing announcement
other announcement
director_dealing announcement
Stockhead
ASX
Google News
Kalkine